Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

• Bing Z. Carter,
• Po Yee Mak,
• Wenjing Tao,
• Edward Ayoub,
• Lauren B. Ostermann,
• Xuelin Huang,
• Sanam Loghavi,
• Steffen Boettcher,
• Yuki Nishida,
• Vivian Ruvolo,
• Paul E. Hughes,
• Phuong K. Morrow,
• Torsten Haferlach,
• Steven Kornblau,
• Muharrem Muftuoglu,
• Michael Andreeff

Affiliations

Bing Z. Carter

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Po Yee Mak

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Wenjing Tao

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Edward Ayoub

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Lauren B. Ostermann

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Xuelin Huang

Department of Biostatistics, The University of Texas MD Anderson Cancer Center

Sanam Loghavi

Department of Hematopathology, The University of Texas MD Anderson Cancer Center

Steffen Boettcher

Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich

Yuki Nishida

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Vivian Ruvolo

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Paul E. Hughes

Oncology Research, Amgen Inc

Phuong K. Morrow

Amgen Inc

Torsten Haferlach

MLL Munich Leukemia Laboratory

Steven Kornblau

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Muharrem Muftuoglu

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center

Michael Andreeff

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center